Severe novel H1N1 influenza A infection in the immediate postoperative period of a liver transplant patient

Rodrigo Zapata, Mario Uribe, Waldo Martínez, Alejandro Andrade, José Luis Leal, Fernando Gomez – 15 January 2010 – In 2009, the World Health Organization recognized the novel H1N1 influenza A virus as a pandemic infection. Since April 2009, thousands of cases of novel H1N1 influenza A infection have been reported worldwide, and they have resulted in thousands of deaths. South American countries were affected by this infection during their winter season, and Chile presented one of the highest incidence rates.

Dual living donor liver transplantation with ABO‐incompatible and ABO‐compatible grafts to overcome small‐for‐size graft and ABO blood group barrier

Gi‐Won Song, Sung‐Gyu Lee, Shin Hwang, Ki‐Hum Kim, Chul‐Soo Ahn, Deok‐Bog Moon, Tae‐Yong Ha, Seog‐Woon Kwon, Gi‐Young Ko, Kyoung‐Won Kim – 15 January 2010 – ABO blood group compatibility has been regarded as an essential prerequisite for successful adult living donor liver transplantation (LDLT). Novel strategies for overcoming the ABO blood group barrier, however, have markedly improved the results of ABO‐incompatible (ABOi) LDLT.

Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha‐2b

Elizabeth B. Haagsma, Annelies Riezebos‐Brilman, Arie P. van den Berg, Robert J. Porte, Hubert G. M. Niesters – 15 January 2010 – Hepatitis E virus (HEV) infections are known to run a self‐limiting course. Recently, chronic hepatitis E has been described in immunosuppressed patients after solid‐organ transplantation. Besides the general recommendation to lower the immunosuppressive medication in these patients, there is currently no specific treatment.

Tumor recurrence following liver transplantation for hepatocellular carcinoma: Role of tumor proliferation status

Aileen E. Marshall, Simon M. Rushbrook, Sarah L. Vowler, Christopher R. Palmer, R. Justin Davies, Paul Gibbs, Susan E. Davies, Nicholas Coleman, Graeme J. M. Alexander – 12 January 2010 – The selection of patients with hepatocellular carcinoma for liver transplantation is currently based on the size and number of tumors to minimize the risk of recurrence. These criteria measure tumor bulk but may not reflect tumor behavior accurately. A biological marker of tumor behavior could aid with patient selection further.

Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody–positive donors: A systematic review

Sammy Saab, Benjamin Waterman, Amanda C. Chi, Myron J. Tong – 12 January 2010 – Orthotopic liver transplantation (OLT) recipients without hepatitis B virus (HBV) infection who receive liver grafts from antibody to hepatitis B core antigen–positive [HBcAb(+)], hepatitis B surface antigen–negative [HBsAg(−)] donors have an increased risk of developing de novo hepatitis B infection.

Acute and long‐term effects of inhaled iloprost in portopulmonary hypertension

Maria Teresa Melgosa, Giovanni L. Ricci, Juan Carlos García‐Pagan, Isabel Blanco, Pilar Escribano, Juan G. Abraldes, Josep Roca, Jaume Bosch, Joan Albert Barberà – 12 January 2010 – Portopulmonary hypertension (PoPH) is a serious condition without an established treatment. Drugs used to treat pulmonary hypertension may have detrimental effects on portal hypertension. This study was designed to assess in patients with PoPH the acute effects of inhaled iloprost (iILO) on pulmonary and hepatic hemodynamics and to evaluate the clinical outcome after 12 months of treatment.

Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: An intention‐to‐treat analysis

Omar Barakat, R. Patrick Wood, Claire F. Ozaki, Victor Ankoma‐Sey, Joseph Galati, Mark Skolkin, Barry Toombs, Mary Round, Warren Moore, Luis Mieles – 12 January 2010 – In selected patients, locoregional therapy (LRT) has been successful in downstaging advanced hepatocellular carcinoma (HCC) so that the conventional criteria for liver transplantation (LT) can be met. However, the factors that predict successful treatment are largely unidentified. To determine these factors, we analyzed our experience with multimodal LRT in downstaging advanced HCC before LT in a retrospective cohort study.

Strategy to prevent recurrent portal vein stenosis following interventional radiology in pediatric liver transplantation

Yukihiro Sanada, Youichi Kawano, Koichi Mizuta, Satoshi Egami, Makoto Hayashida, Taiichi Wakiya, Takehito Fujiwara, Yasunaru Sakuma, Masanobu Hydo, Manabu Nakata, Yoshikazu Yasuda, Hideo Kawarasaki – 12 January 2010 – Portal vein complications after liver transplantation (LT) are serious complications that can lead to graft liver failure. Although the treatment of interventional radiology (IVR) by means of balloon dilatation for portal vein stenosis (PVS) after LT is an effective method, the high rate of recurrent PVS is an agonizing problem.

Subscribe to